Lobelane decreases methamphetamine self-administration in rats
- PMID: 17612524
- PMCID: PMC2104779
- DOI: 10.1016/j.ejphar.2007.06.003
Lobelane decreases methamphetamine self-administration in rats
Abstract
Lobelane, a minor alkaloid of Lobelia inflata and a synthetic, des-oxy analog of lobeline, has good affinity for the vesicular monoamine transporter and the dopamine transporter. The current study examined the ability of lobelane to specifically decrease methamphetamine self-administration. Rats were trained on a fixed ratio 5 schedule of reinforcement to self-administer methamphetamine (0.05 mg/kg/infusion, i.v.) or to respond for sucrose pellets. Upon reaching stable responding, rats were pretreated with lobelane (0.1, 1, 3, 5.6, or 10 mg/kg, s.c.) or saline, 15 min prior to the operant session. To assess the effect of repeated lobelane on methamphetamine self-administration, rats were pretreated with lobelane (5.6 or 10 mg/kg, s.c.) for 7 sessions. Behavioral specificity was further investigated by assessing the effects of lobelane (0.1, 1, 3, 5, or 10 mg/kg, s.c.) or saline on locomotor activity. Within the dose range tested, lobelane dose-dependently decreased methamphetamine self-administration, while having no effect on sucrose-maintained responding. Locomotor activity was decreased following only the highest dose of lobelane (10 mg/kg). Across repeated pretreatments, tolerance developed to the effect of lobelane on methamphetamine self-administration, demonstrating that the ability of lobelane to specifically decrease methamphetamine self-administration is a transient effect. Thus, taken together, the results show that although lobelane interacts with the pharmacological targets believed to be responsible for its ability to decrease methamphetamine self-administration, removal of the oxygen functionalities from the lobeline molecule may have afforded a compound with an altered pharmacokinetic and/or pharmacodynamic profile.
Figures





Similar articles
-
The novel pyrrolidine nor-lobelane analog UKCP-110 [cis-2,5-di-(2-phenethyl)-pyrrolidine hydrochloride] inhibits VMAT2 function, methamphetamine-evoked dopamine release, and methamphetamine self-administration in rats.J Pharmacol Exp Ther. 2010 Dec;335(3):841-51. doi: 10.1124/jpet.110.172742. Epub 2010 Aug 30. J Pharmacol Exp Ther. 2010. PMID: 20805303 Free PMC article.
-
Lobeline attenuates d-methamphetamine self-administration in rats.J Pharmacol Exp Ther. 2001 Jul;298(1):172-9. J Pharmacol Exp Ther. 2001. PMID: 11408539
-
Lobelane inhibits methamphetamine-evoked dopamine release via inhibition of the vesicular monoamine transporter-2.J Pharmacol Exp Ther. 2010 Feb;332(2):612-21. doi: 10.1124/jpet.109.160275. Epub 2009 Oct 23. J Pharmacol Exp Ther. 2010. PMID: 19855096 Free PMC article.
-
The vesicular monoamine transporter-2: an important pharmacological target for the discovery of novel therapeutics to treat methamphetamine abuse.Adv Pharmacol. 2014;69:71-106. doi: 10.1016/B978-0-12-420118-7.00002-0. Adv Pharmacol. 2014. PMID: 24484975 Free PMC article. Review.
-
A novel mechanism of action and potential use for lobeline as a treatment for psychostimulant abuse.Biochem Pharmacol. 2002 Jan 15;63(2):89-98. doi: 10.1016/s0006-2952(01)00899-1. Biochem Pharmacol. 2002. PMID: 11841781 Review.
Cited by
-
Human disease-drug network based on genomic expression profiles.PLoS One. 2009 Aug 6;4(8):e6536. doi: 10.1371/journal.pone.0006536. PLoS One. 2009. PMID: 19657382 Free PMC article.
-
Stereocontrolled synthesis and pharmacological evaluation of cis-2,6-diphenethyl-1-azabicyclo[2.2.2]octanes as lobelane analogues.J Org Chem. 2009 Aug 21;74(16):6072-6. doi: 10.1021/jo901082r. J Org Chem. 2009. PMID: 20560567 Free PMC article.
-
Pyrrolidine analogues of lobelane: relationship of affinity for the dihydrotetrabenazine binding site with function of the vesicular monoamine transporter 2 (VMAT2).J Med Chem. 2009 Dec 10;52(23):7878-82. doi: 10.1021/jm900770h. J Med Chem. 2009. PMID: 19691331 Free PMC article.
-
Design, synthesis and interaction at the vesicular monoamine transporter-2 of lobeline analogs: potential pharmacotherapies for the treatment of psychostimulant abuse.Curr Top Med Chem. 2011;11(9):1103-27. doi: 10.2174/156802611795371332. Curr Top Med Chem. 2011. PMID: 21050177 Free PMC article. Review.
-
Synthesis of Lobeline, Lobelane and their Analogues. A Review.Org Prep Proced Int. 2015;47(5):317-337. doi: 10.1080/00304948.2015.1066642. Epub 2015 Aug 17. Org Prep Proced Int. 2015. PMID: 26858465 Free PMC article. No abstract available.
References
-
- Abood LG, Banerjee S, Kanne DB. Sites, mechanisms, and structural characteristics of the brain's nicotine receptor. J. Subst. Abuse. 1989;1:259–271. - PubMed
-
- Baumann MH, Phillips JM, Ayestas MA, Ali SF, Rice KC, Rothman RB. Preclinical evaluation of GBR12909 decanoate as a long-acting medication for methamphetamine dependence. Ann. N.Y. Acad. Sci. 2002;965:92–108. - PubMed
-
- Damaj MI, Patrick GS, Creasy KR, Martin BR. Pharmacology of lobeline, a nicotinic receptor ligand. J. Pharmacol. Exp. Ther. 1997;282:410–419. - PubMed
-
- Dwoskin LP, Crooks PA. A novel mechanism of action and potential use for lobeline as a treatment for psychostimulant abuse. Biochem. Pharmacol. 2002;63:89–98. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical